COMMUNIQUÉS West-GlobeNewswire

Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
02/10/2025
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
02/10/2025
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
02/10/2025
Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of [...]
Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery
02/10/2025
Study in Nature Biomedical Engineering details Precision’s surface-based system and shows results from the first five patients NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), [...]
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
02/10/2025
TOURS, France, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced that it has secured a [...]
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
02/10/2025
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 [...]
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
02/10/2025
Communiqué de presse Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés Les analyses additionnelles préplanifiées de l’ [...]
e-therapeutics relance son activité sous le nom de Tangram Therapeutics et présente LLibra OS
02/10/2025
Ce renouveau marque une étape décisive dans la croissance de la Société, qui prévoit de soumettre sa première demande d’essai clinique (ou CTA, de l’anglais « Clinical Trial Application ») au quatrième trimestre 2025. [...]
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
02/10/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
02/10/2025
The 2025 Imprivata State of Shared Mobile Devices in Healthcare Report identifies the benefits as well as the challenges Australian healthcare organisations face when implementing shared-use mobile devices for clinical [...]

Pages